Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum

Trends in Parasitology

Volumn 27, Issue 5, 2011, Pages 190-196

  Smith, Thomas A ^a,b   Chitnis, Nakul ^a,b   Briët, Olivier J T ^a,b   Tanner, Marcel ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCIDE; MALARIA VACCINE; TRANSMISSION BLOCKING VACCINE; UNCLASSIFIED DRUG;

DISEASE SIMULATION; DISEASE TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; HUMAN; MALARIA FALCIPARUM; MATHEMATICAL ANALYSIS; MORBIDITY; MOSQUITO; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; REVIEW; VECTOR CONTROL;

ANIMALS; CULICIDAE; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

PLASMODIUM FALCIPARUM;

EID: 79955077976     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.12.011     Document Type: Review

References (20)

1. Saul A. Mosquito stage, transmission blocking vaccines for malaria. Curr. Opin. Infect. Dis. 2007, 20:476-481.
2. Targett G.A., Greenwood B.M. Malaria vaccines and their potential role in the elimination of malaria. Malar. J. 2008, 7(Suppl. 1):S10.
3. Schneider P., et al. Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am. J. Trop. Med. Hyg. 2007, 76:470-474.
4. Mulder B., et al. Plasmodium falciparum: membrane feeding assays and competition ELISAs for the measurement of transmission reduction in sera from Cameroon. Exp. Parasitol. 1999, 92:81-86.
5. van der Kolk M., et al. Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data. Parasitology 2005, 130:13-22.
6. Saul A. Efficacy model for mosquito stage transmission blocking vaccines for malaria. Parasitology 2008, 135:1497-1506.
7. Penny M.A., et al. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS ONE 2008, 3:e3193.
8. Dietz K. Models for parasitic disease control. Bull. ISI 1975, 46:531-544.
9. Genton B., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 2002, 185:820-827.
10. Moorthy V.S., Ballou W.R. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar. J. 2009, 8:312.
11. Schofield L. On the function of repetitive domains in protein antigens of Plasmodium and other eukaryotic parasites. Parasitol. Today 1991, 7:99-105.
12. Hastings I.M. Gametocytocidal activity in antimalarial drugs speeds the spread of drug resistance. Trop. Med. Int. Health 2006, 11:1206-1217.
13. Najera, J.A. et al. (1998) Malaria epidemics, detection and control, forecasting and prevention (WHO/MAL/98 edn), World Health Organisation.
14. Ceita J.G.V. Malaria in São Tomé and Principe. Proceedings of the Conference on Malaria in Africa 1986, 142-155. American Institute of Biological Sciences. A.A. Buck (Ed.).
15. Pinikahana J., Dixon R.A. Trends in malaria morbidity and mortality in Sri Lanka. Indian J. Malariol. 1993, 30:51-55.
16. Haji H., et al. Absence of relationships between selected human factors and natural infectivity of Plasmodium falciparum to mosquitoes in an area of high transmission. Parasitology 1996, 113(Pt 5):425-431.
17. Garrett-Jones C. Prognosis for interruption of malaria transmission through assessment of the mosquito's vectorial capacity. Nature 1964, 4964:1173-1175.
18. Smith D.L., et al. Measuring malaria for elimination. Shrinking the Malaria Map A Prospectus on Malaria Elimination 2009, 108-126. The Global Health Group. R. Feachem (Ed.).
19. Chitnis N., et al. Comparing the effectiveness of malaria vector-control interventions through a mathematical model. Am. J. Trop. Med. Hyg. 2010, 83:230-240.
20. Killeen G.F., et al. Infectiousness of malaria-endemic human populations to vectors. Am. J. Trop. Med. Hyg. 2006, 76(Suppl. 2):38-45.